Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 133,325 |
|
|||||
| News | - | ||||||
| Day High | 5.07 | Low High |
|||||
| Day Low | 4.13 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| AEON Biopharma Inc | AEON | AMEX | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.82 | 19.29% | 5.07 | 15:53:18 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.13 | 4.13 | 5.07 | 5.07 | 4.25 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,976 | 133,325 | US$ 4.67 | US$ 622,228 | - | 3.37 - 17.17 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 17:30:00 | 601 | US$ 5.07 | USD |
AEON Biopharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 188.4M | 37.16M | - | 52.75M | 24.05M | 0.65 | 7.83 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
AEON Biopharma News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/22/2023 | 20:48 | Edgar (US Regulatory) | Form S-1/A - General form for registration of securities.. |
| 11/13/2023 | 08:01 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 11/13/2023 | 08:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/19/2023 | 15:23 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/02/2023 | 16:06 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/18/2023 | 16:27 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under.. |
| 8/16/2023 | 06:00 | GlobeNewswire Inc. | Strathspey Crown Holdings Group, LLC Provides Clarifying.. |
| 8/11/2023 | 20:12 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AEON Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.35 | 6.36 | 3.795 | 4.48 | 71,895 | -1.28 | -20.16% |
| 1 Month | 7.45 | 8.70 | 3.795 | 6.63 | 59,301 | -2.38 | -31.95% |
| 3 Months | 7.07 | 17.17 | 3.795 | 11.14 | 63,140 | -2.00 | -28.29% |
| 6 Months | 5.52 | 17.17 | 3.795 | 10.28 | 36,035 | -0.45 | -8.15% |
| 1 Year | 10.14 | 17.17 | 3.37 | 7.79 | 61,395 | -5.07 | -50.00% |
| 3 Years | 10.14 | 17.17 | 3.37 | 7.79 | 61,395 | -5.07 | -50.00% |
| 5 Years | 10.14 | 17.17 | 3.37 | 7.79 | 61,395 | -5.07 | -50.00% |
AEON Biopharma Description
| AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins. When injected at therapeutic levels, ABP-450 blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle. It is also engaged in the Phase II clinical study of ABP-450 for the treatment of cervical dystonia. Cervical dystonia, also known as spasmodic torticollis, is a neurological condition. |
